Aripiprazole

Generic Name
Aripiprazole
Brand Names
Abilify, Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen), Abilify Maintena, Aripiprazole Accord, Aripiprazole Sandoz, Aripiprazole Zentiva
Drug Type
Small Molecule
Chemical Formula
C23H27Cl2N3O2
CAS Number
129722-12-9
Unique Ingredient Identifier
82VFR53I78
Background

Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A ...

Indication

Aripiprazole is indicated for the treatment of acute manic and mixed episodes associated with bipolar I disorder, irritability associated with autism spectrum disorder, schizophrenia, and Tourette's disorder. It is also used as an adjunctive treatment of major depressive disorder.[L45859 An injectable formulation of aripiprazole is indicated for agitation as...

Associated Conditions
Agitation, Bipolar 1 Disorder, Irritability, Major Depressive Disorder (MDD), Mixed manic depressive episode, Psychosis, Psychotic Depression, Schizophrenia, Tourette's Disorder (TD), Acute Manic episode
Associated Therapies
Monotherapy
Clinical Trials
Related News

The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia

Not Applicable
Terminated
Conditions
Schizophrenia
Interventions
Other: fMRI
Drug: Aripiprazole
First Posted Date
2005-09-21
Last Posted Date
2013-12-06
Lead Sponsor
Emory University
Target Recruit Count
20
Registration Number
NCT00209027
Locations
🇺🇸

Atlanta VA Medical Center, Decatur, Georgia, United States

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (SFBRI)

Not Applicable
Terminated
Conditions
Schizophrenia
Schizoaffective Disorder
First Posted Date
2005-09-21
Last Posted Date
2011-09-07
Lead Sponsor
Louisiana State University Health Sciences Center Shreveport
Target Recruit Count
8
Registration Number
NCT00211380
Locations
🇺🇸

Psychopharmacology Research Clinic, Shreveport, Louisiana, United States

Cognitive Improvement With Aripiprazole (Abilify) in Patients With Schizophrenia (BMS)

Not Applicable
Terminated
Conditions
Schizophrenia
Schizoaffective Disorder
First Posted Date
2005-09-21
Last Posted Date
2011-09-07
Lead Sponsor
Louisiana State University Health Sciences Center Shreveport
Target Recruit Count
8
Registration Number
NCT00211302
Locations
🇺🇸

Psychopharmacology Research Clinic, Shreveport, Louisiana, United States

Aripiprazole in Children With Autism: A Pilot Study

Phase 2
Completed
Conditions
Autism
Interventions
Drug: Aripiprazole
First Posted Date
2005-09-21
Last Posted Date
2018-07-30
Lead Sponsor
Drexel University College of Medicine
Target Recruit Count
11
Registration Number
NCT00208533
Locations
🇺🇸

Drexel University College of Medicine at Friends Hospital, Philadelphia, Pennsylvania, United States

Abilify Therapy for Reducing Comorbid Substance Abuse

First Posted Date
2005-09-21
Last Posted Date
2007-08-24
Lead Sponsor
Creighton University
Target Recruit Count
30
Registration Number
NCT00208169
Locations
🇺🇸

Creighton University Psychiatry and Research Center, Omaha, Nebraska, United States

Aripiprazole Treatment of Bipolar Depression

Phase 4
Completed
Conditions
Bipolar Depression
First Posted Date
2005-09-20
Last Posted Date
2007-04-05
Lead Sponsor
Indiana University School of Medicine
Target Recruit Count
10
Registration Number
NCT00198198
Locations
🇺🇸

UH 3124 University Hospital, Indianapolis, Indiana, United States

Metabolic Effects of Antipsychotics in Children

First Posted Date
2005-09-20
Last Posted Date
2018-06-15
Lead Sponsor
Washington University School of Medicine
Target Recruit Count
144
Registration Number
NCT00205699
Locations
🇺🇸

Washington University School of Medicine, Psychiatry Dept., Saint Louis, Missouri, United States

A Study of Aripiprazole in Children and Adolescents With Aspergers and Pervasive Developmental Disorder.

First Posted Date
2005-09-20
Last Posted Date
2014-06-04
Lead Sponsor
Indiana University School of Medicine
Target Recruit Count
25
Registration Number
NCT00198055
Locations
🇺🇸

Riley Hospital, Riley Child and Adolescent Psychiatry Clinic, Indianapolis, Indiana, United States

Evaluating the Effectiveness of Aripiprazole and D-Cycloserine to Treat Symptoms Associated With Autism

First Posted Date
2005-09-20
Last Posted Date
2019-04-09
Lead Sponsor
Indiana University
Target Recruit Count
81
Registration Number
NCT00198107
Locations
🇺🇸

Riley Hospital for Children, Christian Sarkine Autism Treatment Center, Indianapolis, Indiana, United States

Study of Aripiprazole (Abilify) Versus Placebo in Children With Subsyndromal Bipolar Disorder

Phase 3
Completed
Conditions
Bipolar Disorder
Interventions
Drug: Placebo
Drug: Aripiprazole
First Posted Date
2005-09-19
Last Posted Date
2017-06-26
Lead Sponsor
University Hospitals Cleveland Medical Center
Target Recruit Count
62
Registration Number
NCT00194012
Locations
🇺🇸

University Hospitals Case Medical Center - Walker Building, Cleveland, Ohio, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy